These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24077346)

  • 1. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
    Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
    Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
    Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
    Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.
    Hartmann W; Digon-Söntgerath B; Koch A; Waha A; Endl E; Dani I; Denkhaus D; Goodyer CG; Sörensen N; Wiestler OD; Pietsch T
    Clin Cancer Res; 2006 May; 12(10):3019-27. PubMed ID: 16707597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
    Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
    Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
    Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
    Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
    Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
    Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
    Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
    Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
    Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
    Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
    J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.